Monday, November 19th | 11 Kislev 5779

Subscribe
October 20, 2017 11:01 am

Japanese Firm Finalizes Record-Setting $1.1 Billion Acquisition of Israel’s NeuroDerm

avatar by JNS.org

Email a copy of "Japanese Firm Finalizes Record-Setting $1.1 Billion Acquisition of Israel’s NeuroDerm" to a friend

The NeuroDerm website. Photo: NeuroDerm.

JNS.org – Following announcements in July that Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC) would acquire the Israeli pharmaceutical company NeuroDerm for $1.1 billion, the companies announced the deal’s finalization on Wednesday.

The deal — part of MTPC’s business strategy to grow its US-based operations — is the largest-ever acquisition of an Israeli healthcare company.

The Japanese company announced NeuroDerm’s delisting from America’s Nasdaq stock exchange, and said shareholders in the Israeli company would be paid $39 per ordinary share.

Founded in 2003, the Rehovot-based Israeli pharmaceutical company specializes in developing new drug delivery methods and devices for central nervous system disorders, and hopes to launch two new groundbreaking products during the next two years.

Related coverage

November 19, 2018 3:51 pm
0

Iran-Backed Palestinian Terror Groups Targeted Israeli Civilians During Recent Gaza Flare-Up, US Envoy Haley Tells UN Security Council

The recent spate of rocket attacks against Israel conducted by Gaza-based Hamas and Islamic Jihad terrorists was raised at the...

“We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients that urgently need new therapies,” said NeuroDerm CEO Dr. Oded Lieberman following the acquisition announcement in July.

“MTPC has demonstrated development and commercialization expertise in the field of neurology and we are confident that the combination of their resources and the robust data…will help make this important new therapy available as broadly and rapidly as possible,” he added.

Share this Story: Share On Facebook Share On Twitter Email This Article

Let your voice be heard!

Join the Algemeiner

Algemeiner.com